Bio/Pharma Capital Expenditure (CapEx) Trends – 2019 PharmSource Edition

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Capital expenditure by mega cap pharma companies has rapidly increased with investments in biologic API production. In recent years, the largest public companies have heavily invested in biologic and injectable capabilities. The increasing amount of large pharma CapEx projects involving both active pharmaceutical ingredient (API) biologics (protein and peptide) and injectable manufacturing is influenced both by the shift of the drugs pipeline to biologics and to the lucrative nature of biologic and high-potency injectable sales.

This expert trend report is a comprehensive look at the capital expenditure of pharma companies on manufacturing facilities/capabilities, including analysis of market cap patterns, headquarter geography and manufacturing services being invested in. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.

Scope

This 32-page report gives an important expert quantitative analysis on the capital expenditure. Findings are based on the GlobalData’s Financial Analytics tool, financials have been analyzed for 1,345 pharma companies. The 5 tables and 11 figures throughout the report illustrate major points and trends.

This report is required reading for –

  • CMO executives and strategic decision-makers: improves understanding of the dose CMO industry and a critical input for strategic planning efforts.
  • Sourcing and procurement executives in bio/pharmaceutical companies: improving understanding of crucial components of the supply base that will provide insights for supplier selection and management.
  • Suppliers of capital components

Reasons to Buy

Buy this report to answer these key questions:

  • How are trends in CapEx related to company revenue?
  • What has been the CapEx growth trends between 2014-2018?
  • How do trends in CapEx vary by company market cap?
  • How do CapEx trend change by company HQ location?
  • What is the CapEx for leading public CDMOs?
  • Which pharma companies have the highest number of CapEx projects?
  • What CapEx projects were completed 2016–2018 or have a projected completion for 2019–2025 and which manufacturing services and facility locations are involved?

Table of Contents

1 Table of Contents

2 List of Tables

3 List of Figures

4 Executive Summary

5 Introduction

6 CapEx Overview

6.1 Mega Cap

6.2 Large Cap

6.3 Mid Cap

6.4 Small Cap

7 CapEx by Company Headquarter Location

8 CapEx Relative to Other Financial Indicators

9 Nature of Capital Expenditure – What Is Being Built?

10 What it Means

11 Appendix

11.1 Methodology for Dataset Creation

11.2 CapEx Project Tables

11.3 Key Opinion Leaders

11.4 Bibliography

11.5 About the Authors

11.6 Contact Us

11.7 Disclaimer

Table

Table 1: Composition of Bio/Pharma Companies, 2018

Table 2: Analysis of Identified CapEx Projects with 2018 Completion or Later

Table 3: Location of Identified CapEx Projects

Table 4: CapEx Projects Completed 2016–2018

Table 5: CapEx Projects Completed 2019 or Later

Figures

Figure 1: CapEx by Company Market Cap, 2018

Figure 2: Comparison of CapEx Change to Revenue Change, 2014–2018

Figure 3: CapEx Trends at Bio/Pharma Companies, 2014–2018

Figure 4: CapEx Trends at Bio/Pharma Companies 2014–2018 Compared to Base Year 2014

Figure 5: CapEx Spend and Growth Rate for Mega Cap Companies

Figure 6: Total CapEx Spend by Company HQ Location

Figure 7: CapEx as a Proportion of Revenue by Country

Figure 8: Mid Cap CapEx as a Proportion of Revenue by Country

Figure 9: Cash Spent on Dividends, Share Repurchase, and CapEx by Mega Cap Companies (excluding Roche), 2014–2018

Figure 10: Capital Expenditure for Leading Public CDMOs, 2018

Figure 11: Companies with the Highest Number of Projects Completed, 2019–2025

Frequently asked questions

Bio/Pharma Capital Expenditure (CapEx) Trends – 2019 PharmSource Edition thematic reports
Currency USD
$4,995

Can be used by individual purchaser only

$14,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Bio/Pharma Capital Expenditure (CapEx) Trends – 2019 PharmSource Edition was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Bio/Pharma Capital Expenditure (CapEx) Trends – 2019 PharmSource Edition in real time.

  • Access a live Bio/Pharma Capital Expenditure (CapEx) Trends – 2019 PharmSource Edition dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.